Sepideh Parchami Ghazaee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sepideh Parchami Ghazaee has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Kateryna Marchenko-Tolsta
ПВНЗ «Київський медичний університет
8 shared publications - Ella Gorova3 shared publications
- Iryna Tymchenko
Kyiv Medical University, Kyiv, Ukraine
3 shared publications - Лариса Новикова
ПВНЗ «Київський медичний університет», Україна
3 shared publications Larysa Novykova
2 shared publicationsKateryna Marchenko-Tolsta
1 shared publication
Latest Publications
- 3 September 2026
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 2,p. 66-81
Phytotherapy targeting immunosenescence: mechanistic perspectives for healthy ageing (mini-review)
- 3 September 2026
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 2,p. 66-81
Phytotherapy targeting immunosenescence: mechanistic perspectives for healthy ageing (mini-review)
- Open Access
- 10 April 2026
- Published by LLC Information and Research Center Likarska Sprava in Likars'ka Sprava
- No. 2,p. 69–75
Pharmacological mechanisms and therapeutic implications of herbal immunomodulators (mini-review)
Introduction. Immunomodulatory medicinal plants have been extensively investigated in vitro, in animal models, and in human studies. Aromatic and essential oil–containing species, including Laurus nobilis, Nigella sativa, Withania somnifera, Echinacea purpurea, and Andrographis paniculata, comprise bioactive phytochemicals such as terpenoids, flavonoids, and phenolic compounds that influence both innate and adaptive immune responses. Aim of the study. This review aimed to provide a translational analysis of mechanistic, preclinical, and clinical evidence supporting their immunomodulatory potential. Methodology. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science, focusing on experimental and human studies reporting immunological outcomes. Discussion. Preclinical investigations demonstrate that plant-derived compounds modulate macrophage activation, cytokine expression, lymphocyte proliferation, and natural killer (NK) cell activity. For example, andrographolide influences T-cell signalling and cytokine production, while thymoquinone enhances NK cell cytotoxicity and regulates Th1/Th2 balance. Translational human studies report increased lymphocyte counts and cytokine levels following supplementation with standardised extracts. Randomised controlled trials further indicate that Withania somnifera enhances immunoglobulins, T helper cells, and NK cell activity. Echinacea purpurea increases NK cytotoxicity and cytokine production, and Allium-based formulations reduce the incidence and severity of respiratory infections in older adults. From a pharmacological perspective, these plants act as multi-target agents modulating signalling cascades and gene expression. However, variability in extract standardisation, dosage regimens, and bioavailability contributes to heterogeneity in clinical outcomes. Conclusion. Overall, medicinal plants demonstrate regulatory rather than purely stimulatory immune effects, supporting their potential role in integrative immunotherapy. Further large-scale, well-controlled trials using standardised preparations are required to strengthen clinical translation.
- 10 April 2026
- Published by LLC Information and Research Center Likarska Sprava in Likars'ka Sprava
- No. 2,p. 69–75
Open AccessPharmacological mechanisms and therapeutic implications of herbal immunomodulators (mini-review)
Introduction. Immunomodulatory medicinal plants have been extensively investigated in vitro, in animal models, and in human studies. Aromatic and essential oil–containing species, including Laurus nobilis, Nigella sativa, Withania somnifera, Echinacea purpurea, and Andrographis paniculata, comprise bioactive phytochemicals such as terpenoids, flavonoids, and phenolic compounds that influence both innate and adaptive immune responses. Aim of the study. This review aimed to provide a translational analysis of mechanistic, preclinical, and clinical evidence supporting their immunomodulatory potential. Methodology. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science, focusing on experimental and human studies reporting immunological outcomes. Discussion. Preclinical investigations demonstrate that plant-derived compounds modulate macrophage activation, cytokine expression, lymphocyte proliferation, and natural killer (NK) cell activity. For example, andrographolide influences T-cell signalling and cytokine production, while thymoquinone enhances NK cell cytotoxicity and regulates Th1/Th2 balance. Translational human studies report increased lymphocyte counts and cytokine levels following supplementation with standardised extracts. Randomised controlled trials further indicate that Withania somnifera enhances immunoglobulins, T helper cells, and NK cell activity. Echinacea purpurea increases NK cytotoxicity and cytokine production, and Allium-based formulations reduce the incidence and severity of respiratory infections in older adults. From a pharmacological perspective, these plants act as multi-target agents modulating signalling cascades and gene expression. However, variability in extract standardisation, dosage regimens, and bioavailability contributes to heterogeneity in clinical outcomes. Conclusion. Overall, medicinal plants demonstrate regulatory rather than purely stimulatory immune effects, supporting their potential role in integrative immunotherapy. Further large-scale, well-controlled trials using standardised preparations are required to strengthen clinical translation.
- Open Access
- 23 February 2025
- Published by European Scientific Platform (Publications) in Grail of Science
- No. 49,p. 1195-1197
EDUCATIONAL PLAN FOR PHARMACOGENETICS IN DEVELOPING COUNTRIES
Pharmacogenetics and pharmacogenomics (PGx) explore genetic polymorphism among individuals, influencing drug transport and metabolism and ultimately affecting drug response. This process involves identifying biomarkers that encode metabolizing enzymes and membrane transporter proteins, allowing for the prediction of treatment efficacy and drug toxicity.
- 23 February 2025
- Published by European Scientific Platform (Publications) in Grail of Science
- No. 49,p. 1195-1197
Open AccessEDUCATIONAL PLAN FOR PHARMACOGENETICS IN DEVELOPING COUNTRIES
Pharmacogenetics and pharmacogenomics (PGx) explore genetic polymorphism among individuals, influencing drug transport and metabolism and ultimately affecting drug response. This process involves identifying biomarkers that encode metabolizing enzymes and membrane transporter proteins, allowing for the prediction of treatment efficacy and drug toxicity.
- 1 January 2025
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 2,p. 64-74
Integrating pharmacogenetics into medical education: an updated systematic review of cross-sectional studies
- 1 January 2025
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 2,p. 64-74
Integrating pharmacogenetics into medical education: an updated systematic review of cross-sectional studies
- Open Access
- 26 April 2024
- Published by European Scientific Platform (Publications)
- No. April 26, ,p. 417-418
ANTI-INFLAMMATORY PROPERTIES OF PHYTOCONSTITUENTS IN MANAGING RHEUMATOID ARTHRITIS
Combining phytochemicals with conventional therapy may create a synergistic, anti-inflammatory and anti-arthritic effect in treating rheumatoid arthritis (RA), while potentially mitigating the associated toxicity [2].
- 26 April 2024
- Published by European Scientific Platform (Publications)
- No. April 26, ,p. 417-418
Open AccessANTI-INFLAMMATORY PROPERTIES OF PHYTOCONSTITUENTS IN MANAGING RHEUMATOID ARTHRITIS
Combining phytochemicals with conventional therapy may create a synergistic, anti-inflammatory and anti-arthritic effect in treating rheumatoid arthritis (RA), while potentially mitigating the associated toxicity [2].
- Open Access
- 28 March 2024
- Published by Bentham Science Publishers Ltd. in New Emirates Medical Journal
- Vol. 05 (1) , 1-10
A Systematic Review of the Novel Targeted Immunobiological Medications in Rheumatoid Arthritis: Efficacy, Safety, and Innovation
Introduction: Over the last half-century, the treatment and management of autoimmune rheumatic diseases have progressively improved, particularly with the contribution of immunobiological or biological therapies known as disease-modifying antirheumatic drugs. Although these agents have been generally efficient in the management of rheumatoid arthritis (RA), some patients experience limited efficacy and non-responsiveness to treatment. In addition, they may cause adverse clinical effects, further aggravating the disease. Objectives: Despite advancements in biological therapies, significant clinical needs persist. This review aims to discuss novel treatments, guiding future guidelines and drug discoveries for rheumatoid arthritis. Methods: This review follows the 2020 PRISMA statement, utilising PubMed and Google Scholar for literature search and emphasizing recent meta-analyses on the safety and efficacy of targeted immunobiological medications. Results: Small molecule inhibitors, whether utilised independently or in conjunction with Methotrexate, have been shown to contribute to effective disease management and have the potential for better adherence to the American College of Rheumatology criteria. Tocilizumab therapy demonstrates a significant reduction in disease activity and improves rates of disease remission when combined with Methotrexate. Investigations of mesenchymal stromal cell therapies have had promising outcomes, improving both cartilage quality (as evaluated by Macroscopic Cartilage Repair Assessment) and joint tenderness and swelling in clinical joint counts. Intra-articular administration of tolerogenic dendritic cells has displayed a capacity to alleviate pain, as measured by Visual Analog Scale scores, and enhance the Disease Activity Score across 28 joints. Resveratrol capsules supplemented with allopathic therapy show potential in reducing TNF-α and interleukin-6 serum levels. Conclusion: More investigations and their analysis will improve patient outcomes and reduce adverse effects and the costs involved in developing and obtaining immunobiological drugs. Moreover, assessing the safety and efficacy of anti-RA properties of the bioactive compounds could offer less toxic and more cost-effective natural treatment options.
- 28 March 2024
- Published by Bentham Science Publishers Ltd. in New Emirates Medical Journal
- Vol. 05 (1) , 1-10
Open AccessA Systematic Review of the Novel Targeted Immunobiological Medications in Rheumatoid Arthritis: Efficacy, Safety, and Innovation
Introduction: Over the last half-century, the treatment and management of autoimmune rheumatic diseases have progressively improved, particularly with the contribution of immunobiological or biological therapies known as disease-modifying antirheumatic drugs. Although these agents have been generally efficient in the management of rheumatoid arthritis (RA), some patients experience limited efficacy and non-responsiveness to treatment. In addition, they may cause adverse clinical effects, further aggravating the disease. Objectives: Despite advancements in biological therapies, significant clinical needs persist. This review aims to discuss novel treatments, guiding future guidelines and drug discoveries for rheumatoid arthritis. Methods: This review follows the 2020 PRISMA statement, utilising PubMed and Google Scholar for literature search and emphasizing recent meta-analyses on the safety and efficacy of targeted immunobiological medications. Results: Small molecule inhibitors, whether utilised independently or in conjunction with Methotrexate, have been shown to contribute to effective disease management and have the potential for better adherence to the American College of Rheumatology criteria. Tocilizumab therapy demonstrates a significant reduction in disease activity and improves rates of disease remission when combined with Methotrexate. Investigations of mesenchymal stromal cell therapies have had promising outcomes, improving both cartilage quality (as evaluated by Macroscopic Cartilage Repair Assessment) and joint tenderness and swelling in clinical joint counts. Intra-articular administration of tolerogenic dendritic cells has displayed a capacity to alleviate pain, as measured by Visual Analog Scale scores, and enhance the Disease Activity Score across 28 joints. Resveratrol capsules supplemented with allopathic therapy show potential in reducing TNF-α and interleukin-6 serum levels. Conclusion: More investigations and their analysis will improve patient outcomes and reduce adverse effects and the costs involved in developing and obtaining immunobiological drugs. Moreover, assessing the safety and efficacy of anti-RA properties of the bioactive compounds could offer less toxic and more cost-effective natural treatment options.
- 1 January 2024
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 1,p. 52-61
INVOLVEMENT OF PHARMACOGENETICS IN PHARMACOLOGICAL ACTIONS OF MEDICINAL PLANTS (A NARRATIVE REVIEW)
- 1 January 2024
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 1,p. 52-61
INVOLVEMENT OF PHARMACOGENETICS IN PHARMACOLOGICAL ACTIONS OF MEDICINAL PLANTS (A NARRATIVE REVIEW)
- Open Access
- 12 May 2023
- Published by European Scientific Platform (Publications) in Grail of Science
- No. 27,p. 632-634
BIOLOGICAL ACTIVE SUBSTANCES OF NATURAL ORIGIN AND RHEUMATOID ARTHRITIS, PREVENTION OR TREATMENT?
According to population-based studies, the global prevalence of RA between 1980 and 2019 was 460 per 100,000 population. Trend analysis showed that RA was observed more in developed countries than developing countries (Almutairi, 2020, pp. 863-877). Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the symptomatic treatment options for RA. However, these medications are known to have multiple adverse effects including nephrotoxicity, gastrointestinal bleeding and ulceration, increasing blood pressure and the risk of first hospitalization due to congestive heart failure. Conventional disease modifying anti-rheumatic drugs (DMARDs) are usually the first choice to diminish disability and improve long-term outcomes for people with RA. Biologics are much more costly than other subsets of DMARDs, they are commonly used as partial responders to traditional DMARDs. Although the combination of biologics and traditional DMARDs has demonstrated improved efficacy, the potential benefits and harms (such as cancer and infections) are still controversial. However, in spite of applying aggressive pharmacologic treatment regimens early in disease onset, complete clinical remission is not achieved (Guo et al., 2018, p.15). Although biological medications seem to effectively target molecular pathways involved in the inflammatory process of RA, there is a lack of long-term safety data regarding their use. Various investigations have demonstrated an increased prevalence in the use of herbal medicine in developing countries. Interestingly, a rise in the prevalence of herbs used as complementary and alternative medicine among chronic disease patients has been reported in recent years. The anti-inflammatory properties of some herbal products are well-known and they have fewer unwanted effects than existing anti-inflammatory medications. As such, herbs and their derivatives constitute a promising arena in novel medical therapies. Furthermore, the cost-effectiveness of natural products has been explored and summarized by high quality studies. Certain phytochemicals are considered to inhibit the release of inflammatory molecules to suppress inflammatory responses (Gandhi et al., 2022, pp.1-15). is the precursor of ellagitannin and has been reported to be the most active polyphenol obtained from different parts of the pomegranate tree (Punica granatum Linn.). Methanolic (and ethanolic) pomegranate peels extract contains a high amount of bioactive compounds including punicalagin (10-50 mg∕g) ( Xu et al., 2021, pp.1-12). Historically, seeds and juices are believed to have been taken as supplements to reduce the clinical symptoms of RA (Singh, Singh, & Mahajan, 2020, pp. 1306-1327). Marques and coauthors (2016) have already revealed that Punicalagin diminished TNF α and interleukin (IL) 6 secretion in macrophages and primary human chondrocytes with lipopolysaccharide (LPS)-induced inflamed RAW264.7. (Marques et al., 2016, pp- 463-1467). Anthocyanins have been shown to represent potent anti-inflammatory, anti-oxidant, anti-cancer, anti-obesity and immunomodulatory activity. (Salehi et al., 2020, pp.1-20). Min and coauthors (2015) reported inhibitory effect of ACNs on osteoclasts via the downregulation of cytokines including IL-1, IL-6, IL-17, and TNF-α in vitro. the study showed EA reduced cartilage destruction, synovial hyperplasia and bone erosion generated by Freund’s adjuvant. Significant suppression of caspase-3 expression in models treated with EA testifies to the anti-apoptotic property of this biologic compound (Fikry, Gad, & Eid, 2019, pp. 878–886).
- 12 May 2023
- Published by European Scientific Platform (Publications) in Grail of Science
- No. 27,p. 632-634
Open AccessBIOLOGICAL ACTIVE SUBSTANCES OF NATURAL ORIGIN AND RHEUMATOID ARTHRITIS, PREVENTION OR TREATMENT?
According to population-based studies, the global prevalence of RA between 1980 and 2019 was 460 per 100,000 population. Trend analysis showed that RA was observed more in developed countries than developing countries (Almutairi, 2020, pp. 863-877). Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the symptomatic treatment options for RA. However, these medications are known to have multiple adverse effects including nephrotoxicity, gastrointestinal bleeding and ulceration, increasing blood pressure and the risk of first hospitalization due to congestive heart failure. Conventional disease modifying anti-rheumatic drugs (DMARDs) are usually the first choice to diminish disability and improve long-term outcomes for people with RA. Biologics are much more costly than other subsets of DMARDs, they are commonly used as partial responders to traditional DMARDs. Although the combination of biologics and traditional DMARDs has demonstrated improved efficacy, the potential benefits and harms (such as cancer and infections) are still controversial. However, in spite of applying aggressive pharmacologic treatment regimens early in disease onset, complete clinical remission is not achieved (Guo et al., 2018, p.15). Although biological medications seem to effectively target molecular pathways involved in the inflammatory process of RA, there is a lack of long-term safety data regarding their use. Various investigations have demonstrated an increased prevalence in the use of herbal medicine in developing countries. Interestingly, a rise in the prevalence of herbs used as complementary and alternative medicine among chronic disease patients has been reported in recent years. The anti-inflammatory properties of some herbal products are well-known and they have fewer unwanted effects than existing anti-inflammatory medications. As such, herbs and their derivatives constitute a promising arena in novel medical therapies. Furthermore, the cost-effectiveness of natural products has been explored and summarized by high quality studies. Certain phytochemicals are considered to inhibit the release of inflammatory molecules to suppress inflammatory responses (Gandhi et al., 2022, pp.1-15). is the precursor of ellagitannin and has been reported to be the most active polyphenol obtained from different parts of the pomegranate tree (Punica granatum Linn.). Methanolic (and ethanolic) pomegranate peels extract contains a high amount of bioactive compounds including punicalagin (10-50 mg∕g) ( Xu et al., 2021, pp.1-12). Historically, seeds and juices are believed to have been taken as supplements to reduce the clinical symptoms of RA (Singh, Singh, & Mahajan, 2020, pp. 1306-1327). Marques and coauthors (2016) have already revealed that Punicalagin diminished TNF α and interleukin (IL) 6 secretion in macrophages and primary human chondrocytes with lipopolysaccharide (LPS)-induced inflamed RAW264.7. (Marques et al., 2016, pp- 463-1467). Anthocyanins have been shown to represent potent anti-inflammatory, anti-oxidant, anti-cancer, anti-obesity and immunomodulatory activity. (Salehi et al., 2020, pp.1-20). Min and coauthors (2015) reported inhibitory effect of ACNs on osteoclasts via the downregulation of cytokines including IL-1, IL-6, IL-17, and TNF-α in vitro. the study showed EA reduced cartilage destruction, synovial hyperplasia and bone erosion generated by Freund’s adjuvant. Significant suppression of caspase-3 expression in models treated with EA testifies to the anti-apoptotic property of this biologic compound (Fikry, Gad, & Eid, 2019, pp. 878–886).
- Open Access
- 26 August 2022
- Published by European Scientific Platform (Publications) in Grail of Science
- No. 18-19,p. 391-393
A REVIEW OF THE ANTICANCER NATURAL PRODUCTS: ALKALOIDS, FLAVONOIDS
According to the international agency for research on cancer 1 in 5 people develop cancer during their lifetime, suggesting that more than 50 million people are living within five years of a past cancer diagnosis (World Health Organization (WHO, 2020, para. 1). Despite novel approaches like nanomedicine, targeted therapy, and immunotherapy in cancer treatments during the last decades, chemoresistance has remained the chief hurdle in eliminating cancerous cells (Elgendy , Alyammahi & Alhamad, 2020, p. 103095). About 9 out of 10 cancer deaths are due to spreading of cancer cells from the primary tumor mass towards close and far tissues (a process called metastasis). Treatment failure followed by consequent recurrence of cancer cells and metastasis is the leading cause of death. Many survivors suffer from serious acute or chronic complications after cancer therapy (Qian, Mei, & Zhang, 2017, p.38). Furthermore, chemotherapy commonly induces a variety of side-effects in patients as a result of nonspecific action against both normal cells and cancerous cells. For instance, chemotherapeutic drugs result in alopecia by affecting not only fast dividing cancer cells, but hair follicles as well. Nausea and vomiting are the most common symptoms induced by chemotherapy, with gastrointestinal symptoms including diarrhea (and in some cases constipation) being another common side effect. Chemotherapy is also known to impair immune function and bone marrow activity (Li et al., 2020, p.599073). The identification of approved doses of anticancer drugs is another point to be given careful attention, especially those with higher cost and administered for a longer duration. Larger doses of chemotherapeutic drugs may increase the risk and severity of the aforementioned side effects, and are not cost-saving. Therefore, phytomedicines should be considered as an option not only for adjuvant therapy, but also in view of their comparatively low toxicity and ability to diminish adverse effects of chemotherapy in cancer patients. Natural products and their derivatives can be used as novel therapeutic interventions with improved pharmacological properties targeting tumor cells (Meriggi & Zaniboni, 2020, pp.1–11).
- 26 August 2022
- Published by European Scientific Platform (Publications) in Grail of Science
- No. 18-19,p. 391-393
Open AccessA REVIEW OF THE ANTICANCER NATURAL PRODUCTS: ALKALOIDS, FLAVONOIDS
According to the international agency for research on cancer 1 in 5 people develop cancer during their lifetime, suggesting that more than 50 million people are living within five years of a past cancer diagnosis (World Health Organization (WHO, 2020, para. 1). Despite novel approaches like nanomedicine, targeted therapy, and immunotherapy in cancer treatments during the last decades, chemoresistance has remained the chief hurdle in eliminating cancerous cells (Elgendy , Alyammahi & Alhamad, 2020, p. 103095). About 9 out of 10 cancer deaths are due to spreading of cancer cells from the primary tumor mass towards close and far tissues (a process called metastasis). Treatment failure followed by consequent recurrence of cancer cells and metastasis is the leading cause of death. Many survivors suffer from serious acute or chronic complications after cancer therapy (Qian, Mei, & Zhang, 2017, p.38). Furthermore, chemotherapy commonly induces a variety of side-effects in patients as a result of nonspecific action against both normal cells and cancerous cells. For instance, chemotherapeutic drugs result in alopecia by affecting not only fast dividing cancer cells, but hair follicles as well. Nausea and vomiting are the most common symptoms induced by chemotherapy, with gastrointestinal symptoms including diarrhea (and in some cases constipation) being another common side effect. Chemotherapy is also known to impair immune function and bone marrow activity (Li et al., 2020, p.599073). The identification of approved doses of anticancer drugs is another point to be given careful attention, especially those with higher cost and administered for a longer duration. Larger doses of chemotherapeutic drugs may increase the risk and severity of the aforementioned side effects, and are not cost-saving. Therefore, phytomedicines should be considered as an option not only for adjuvant therapy, but also in view of their comparatively low toxicity and ability to diminish adverse effects of chemotherapy in cancer patients. Natural products and their derivatives can be used as novel therapeutic interventions with improved pharmacological properties targeting tumor cells (Meriggi & Zaniboni, 2020, pp.1–11).